4//SEC Filing
Quan Lucinda Y. 4
Accession 0001567619-20-018004
CIK 0001799448other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:56 PM ET
Size
15.5 KB
Accession
0001567619-20-018004
Insider Transaction Report
Form 4
Quan Lucinda Y.
See Remarks
Transactions
- Conversion
Series B-1 Preferred Stock
2020-10-20−1,697→ 0 total(indirect: See footnote)→ Common Stock (1,697 underlying) - Conversion
Common Stock
2020-10-20+726→ 9,258 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-10-20−6,835→ 0 total(indirect: See footnote)→ Common Stock (6,835 underlying) - Conversion
Series B-2 Preferred Stock
2020-10-20−726→ 0 total(indirect: See footnote)→ Common Stock (726 underlying) - Conversion
Common Stock
2020-10-20+1,697→ 8,532 total(indirect: See footnote) - Conversion
Common Stock
2020-10-20+6,835→ 6,835 total(indirect: See footnote)
Holdings
- 375,547
Common Stock
Footnotes (2)
- [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
- [F2]Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010.
Documents
Issuer
Aligos Therapeutics, Inc.
CIK 0001799448
Entity typeother
Related Parties
1- filerCIK 0001824711
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 4:56 PM ET
- Size
- 15.5 KB